AI Article Synopsis

  • * Data from 120 T2DM patients, aged 30-60, was analyzed over a year, showing that women taking 10 mg of Empagliflozin had a notable decrease in ALT levels when compared to men not on the medication.
  • * The findings suggest that starting SGLT2-I treatment can lower ALT levels in these patients, highlighting the potential benefit of early intervention along with lifestyle changes to improve liver health and reduce

Article Abstract

Objective: We aimed to elucidate the effectiveness of Sodium-glucose co-transporter-2 inhibitors (SGLT2-I) in the reduction of ALT among Type-2 diabetes patients (T2DM) with Non-alcoholic fatty liver disease (NAFLD).

Methods: We retrospectively collected data from 120 files of T2DM, aged 30-60 years, with elevated ALT, and documented follow-up for one year from August 2018 - July 2019. The effects of SGLT2Is (Dapagliflozin and Empagliflozin) were evaluated using Generalized Estimating Equation (GEE) for analysis.

Results: The overall mean age was 48.9 ± 7.3 years, 57.5% were females, and the mean duration of diabetes was 8.5 ± 5.6 years. At baseline, the mean BMI was 32.5 ± 5.7 kg/m, mean ALT was 51.6 IU/L ± 17.8 IU/L, and mean HbA1c was 8.5% ± 1.5%. There was a statistically significant reduction in mean ALT of 2.2 IU/L (p-value 0.02) with every 10 mg/dl increase in LDL among females using 10 mg Empagliflozin as compared to males not on SGLT2i.

Conclusions: We observed an average reduction in mean ALT levels when SGLT2Is was initiated in T2DM patients having NAFLD. Apart from encouraging diet and lifestyle modification, early intervention with SGLT2Is may decrease liver-related morbidity and mortality resulting from NAFLD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11613383PMC
http://dx.doi.org/10.12669/pjms.40.11.8900DOI Listing

Publication Analysis

Top Keywords

reduction alt
12
type-2 diabetes
8
diabetes patients
8
fatty liver
8
liver disease
8
alt
5
impact sodium-glucose
4
sodium-glucose co-transporter
4
co-transporter type-2
4
type-2 inhibitors
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!